FLT3 ITD-TKD Mutation Molecular Detection
Desired Epic Build
* = editable field
| Cerner Primary Mnemonic: | HLX FLT3 CASE |
| PDM | 1863168 |
| Informatics - Workgroup | Molpath inhouse |
| Synonyms * | FLT3 CASE FLT3 TKD, FLT3 D835, FLT3 Mutant, FLT3 ITD FLT3 |
| Display Name * | FLT3 ITD-TKD Mutation Molecular Detection |
| Specimen Sources (combined Order Entry and Specimen Navigator) * |
Bone Marrow
|
| Specimen Types (combined Order Entry and Specimen Navigator) * |
Bone Marrow
Blood
|
| Body Fluids (types sent through AOEs) | |
| Specimen Navigator Specimen Types |
Aspirate
|
| Specimen Navigator Specimen Sources |
Isthmus
Left
Nasal
No Laterality
Right
Total
Abdomen/Peritoneum
Abscess
Adrenal
Amniotic Sac
Anus
Appendix
Axilla
Bile Duct
Bone
Bone Marrow
Brain
Breast
Bronchial
Buccal
Colon
Duodenum
Ear
Esophagus
Extranodal Lymphoid
Eye
Fallopian Tube
Gallbladder
Gingiva
Ileum
Jejunum
Joint
Kidney
Larynx
Liver
Lung
Lymph Node
Mediastinum
Meninges/Dura
Misc
Muscle
Nasopharynx
Nipple
Nose
Oropharynx/Throat
Ovary
Palate
Pancreas
Pancreatic Duct
Parathyroid
Paratubal Cyst
Pelvic
Penis
Pericardium
Pharynx
Pleura
Prostate
Rectum
Retroperitoneum
Salivary Gland
Sinus
Skin
Soft Tissue
Spleen
Stomach
Testis
Thymus
Thyroid
Tongue
Tonsil
Trachea
Uterus
Vagina
Vas Defe
|
| Specimen Navigator Short Name | FLT3 ITD-TKD Mutation |
| Ordering info (EPIC SmartText) | Acute myelogenous leukemia (AML) is a rare but devastating disease resulting in 1.2% of all cancer related deaths. One of the most common genes mutated in AML is the FMS-Iike tyrosine kinase 3, FLT3. FLT3 is a type Ill tyrosine kinase receptor expressed on the surface of hematopoietic stem cells that regulates differentiation and proliferation of hematopoietic elements. A point mutation in the activation loop of the tyrosine kinase domain (TKD) or an internal tandem duplications (ITD) in the juxtamembrane domain cause constitutive activation of the FLT3 receptor. Studies have shown that AML patients with FLT3-ITD have a lower complete remission rate (78% vs 84%), shorter disease-free survival (30% vs 46% at 5 years) and lower overall survival rate (33% vs 44%) at 5 years. FLT3-TKD mutation has unclear prognosis. Assessing the mutation status of FLT3 may impact diagnosis, prognosis and therapy of patients affected with AML. FLT3-ITD or TKD positive patients may be eligible for therapy with XOSPATA, an FDA-approved drug that inhibits ITD and TKD mutations. |
| IP Orderable (inpatient) | Yes |
| OP Orderable (outpatient) | Yes |
| AOEs * | |
| AP AOEs | |
| Special History | Yes |
| Build Comments | |
| Filter * | genetics |
| Cerner Site Restrict | |
| Cerner Results | |
Actual Epic Build 4/21/2025
| PROCEDURE ID | 115139 | ||||||||||||
| PDM | 1863168 | ||||||||||||
| ORDER DISPLAY NAME | FLT3 ITD-TKD Mutation Molecular Detection | ||||||||||||
| PROCEDURE NAME | FLT3 ITD MUTATION ANALYSIS | ||||||||||||
| PROCEDURE MASTER NUMBER | LAB11399 | ||||||||||||
| SHORT PROCEDURE NAME | FLT3 ITD MUTATION ANALYSIS | ||||||||||||
| CATEGORY CODE | 21.0 | ||||||||||||
| CATEGORY CODE RECORD NAME | LAB MOLECULAR DIAGNOSTICS ORDERABLES | ||||||||||||
| SYNONYMS | HLX FLT3 CASE FLT3 TKD, FLT3 D835, FLT3 MUTANT, FLT3 ITD HLX FLT3 |
||||||||||||
| CLINICALLY ACTIVE | Yes | ||||||||||||
| ORDERABLE | Yes | ||||||||||||
| PERFORMABLE | Yes | ||||||||||||
| FILTER GENOMICS | Generic Genomics Procedure | ||||||||||||
| REFERENCE LINK URL | https://labs.northwell.edu/epic/test/115139 | ||||||||||||
| ORDERING INSTRUCTIONS | |||||||||||||
| DEFAULT SPECIMEN TYPE | Blood | ||||||||||||
| SPECIMEN TYPE PICK LIST | Bone Marrow Blood Aspirate |
||||||||||||
| SPECIMEN TYPE LIST | |||||||||||||
| OP SPECIMEN TYPE LIST | |||||||||||||
| SPECIMEN SOURCE PICK LIST | Bone Marrow Aspirate Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous Bone Marrow |
||||||||||||
| SPECIMEN SOURCE DEFAULT - MALE | Blood, Venous | ||||||||||||
| SPECIMEN SOURCE DEFAULT - FEMALE | Blood, Venous | ||||||||||||
| SPECIMEN SOURCE LIST | |||||||||||||
| OP SPECIMEN SOURCE LIST | |||||||||||||
| IP LAB TEST COMPONENTS FOR REPORT | HLXFLT3FINA:10 | ||||||||||||
| OP LAB TEST COMPONENTS FOR REPORT | HLXFLT3FINA:10 | ||||||||||||
| ORDER QUESTIONS | ["3048500000"] | ||||||||||||
| ORDER QUESTIONS RECORD NAME | |||||||||||||
| INPATIENT ORDER QUESTIONS | ["3048500000"] | ||||||||||||
| INPATIENT ORDER QUESTIONS RECORD NAME | |||||||||||||
| ORDER SPECIFIC QUESTION OVERRIDE | |||||||||||||
| INPATIENT QUESTION OVERRIDE | |||||||||||||
| LOCATION RESTRICT LIST IP | |||||||||||||
| LOCATION RESTRICT LIST IP RECORD NAME | |||||||||||||
| LOCATION RESTRICT LIST INCLUDE IP | |||||||||||||
| LOCATION RESTRICT LIST OP | |||||||||||||
| LOCATION RESTRICT LIST OP RECORD NAME | |||||||||||||
| LOCATION RESTRICT LIST INCLUDES OP | |||||||||||||
| EDP AMB ORDER SPECIFIC QUESTIONS RECORD NAME | NH IP PATIENT COMPLETED CONSENT | ||||||||||||
| EDP IP ORDER SPECIFIC QUESTIONS RECORD NAME | NH IP PATIENT COMPLETED CONSENT | ||||||||||||
| EDP IP SPECIMEN SOURCE | |||||||||||||
| EDP OP SPECIMEN SOURCE | |||||||||||||
| EDP IP SPECIMEN TYPE | |||||||||||||
| EDP OP SPECIMEN TYPE | |||||||||||||
| DERIVED EDP IP BUTTONS S | |||||||||||||
| DERIVED EDP IP BUTTONS T | |||||||||||||
| DERIVED EDP OP BUTTONS S | |||||||||||||
| DERIVED EDP OP BUTTONS T | |||||||||||||
| IP ORDERABLE | 1 | ||||||||||||
| OP ORDERABLE | 1 | ||||||||||||
| STANDARD LAB COMPONENTS | |||||||||||||
| STANDARD LAB COMPONENTS RECORD NAME | |||||||||||||
| COMPONENT DATA REQUIREMENT | |||||||||||||
EPIC OP AOEs
| |||||||||||||
EPIC IP AOEs
| |||||||||||||
| EPIC Components (results - crosswalked through Cerner) | |||||||||||||